Visión generalGráficoNoticiasTraderScreen

Morgan Stanley Discount Zert RTX .../  DE000ME7GQH2  /

Stuttgart
23/05/2024  20:34:07 Diferencia+0.19 Bid22:00:33 Ask22:00:33 Subyacente Precio de ejercicio Fecha de expiración Tipo de opción
72.75EUR +0.26% -
Volumen de oferta: -		 -
Tamaño/ Volumen/ Formato de Ask: -		 RTX Corporation - USD 27/09/2024 Call
GlobeNewswire 23:25 MTTR Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Matterport to CoSta...
GlobeNewswire 23:23 DOCS INVESTOR NEWS: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Doximity, Inc. Investors to Se...
GlobeNewswire 23:22 HRBR Stockholders: Robbins LLP Reminds HRBR Stockholders of Securities Fraud Class Action Against Ha...
GlobeNewswire 23:21 INTC Stockholders: Robbins LLP Reminds INTC Stockholders of Securities Fraud Class Action Against In...
GlobeNewswire 23:18 Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
Newsfile Corp 23:15 American Aires Extends Global Expansion by Opening Latest International Fulfillment Center in the UK
GlobeNewswire 23:15 Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of ...
GlobeNewswire 23:13 SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Onc...
TeleTrader 23:13 SEC approves spot Ethereum ETFs
GlobeNewswire 23:11 Special Olympics Florida and Orlando Health Announce Five-Year Partnership
GlobeNewswire 23:10 Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-10...
GlobeNewswire 23:09 Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant impr...
GlobeNewswire 23:06 G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (A...
GlobeNewswire 23:05 Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
GlobeNewswire 23:05 BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upco...
GlobeNewswire 23:05 I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at A...
GlobeNewswire 23:05 Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrat...
GlobeNewswire 23:05 Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
GlobeNewswire 23:05 FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) ...
GlobeNewswire 23:05 NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Adva...
GlobeNewswire 23:05 Elcora Announces Share Consolidation
GlobeNewswire 23:05 Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study i...
GlobeNewswire 23:04 Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combinatio...
GlobeNewswire 23:03 Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...
GlobeNewswire 23:01 Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitab...